On Aug. 27, 2024, a panel of the Inquiry Committee approved a consent agreement between BCCNM and the registrant to address conduct and fitness concerns that occurred in 2023 relating to diversion of narcotics and controlled substances from the workplace for personal use.
The registrant was diagnosed with and admitted to a disability with a causal relationship to the practice issues via an independent medical evaluation and they have agreed to comply with the treatment recommendations.
The registrant has voluntarily agreed to terms equivalent to a limit and/or condition on their practice, including:
- A reprimand.
- Enrollment in a medical monitoring agreement with an independent medical monitoring agency for a minimum term of 36 months with regular reports of compliance being provided to BCCNM.
- Disclosure of treatment recommendations to relevant employer representative(s).
- A limit restricting access to and handling of narcotics, benzodiazepines, controlled substances, and the “zed" class of drugs, with concurrent medical monitoring, for a term to support the stable return to work and ongoing fitness to practice.
- A limit that they not work overtime, act as the nurse-in-charge, work night shifts, have supervision over students, or be involved in the orientation of staff for a term.
- Adherence to the employer's learning plan.
The agreement will remain in place for a minimum of four years of continuous nursing practice.
The name of the registrant has been withheld in accordance with section 39.3 (4) (a) of the Health Professions Act for the purposes of not identifying a registrant or their personal health information respecting the condition that impaired their ability to practice nursing or midwifery.
The Inquiry Committee is satisfied that the terms will protect the public.